List view / Grid view

Peter B. Simpson

 

article

High content cell based primary screening for oncology targets – a perspective

Over the last 15 years, vendors have offered microscope-based instruments…

25 June 2010 | By Peter Alcock, Colin Bath, Carolyn Blackett & Peter B. Simpson, Screening & Assay Sciences, Cancer Bioscience, AstraZeneca Alderley Park

Over the last 15 years, vendors have offered microscope-based instruments capable of producing images of fluorescent labelled components of cells grown in microtitre plates. These instruments are typically bundled with analysis software capable of defining the relative distribution of several fluorescent markers on a cell by cell basis1,2. As the…

article

Getting a handle on neuronal behaviour in culture

In drug discovery for CNS diseases, the use of complex…

20 May 2005 | By Peter B. Simpson, Senior Research Fellow – Automated imaging, Neuroscience Research Centre, Merck Sharp and Dohme

In drug discovery for CNS diseases, the use of complex neural cell culture systems offers many advantages. Innovations in high content screening enable us to identify compounds which affect key cell biological properties in such cultures. We can bridge the divide between kinetic and endpoint screening by use of another…